What question did this study set out to answer?

The study aims to investigate the synergistic effects of pemetrexed and osimertinib combinations and the underlying pharmacokinetic/pharmacodynamic mechanisms.

March 28, 2026Open Access

A Mechanistic Pharmacokinetic/Pharmacodynamic Model for Sequence-Dependent Synergy in Pemetrexed–Osimertinib Combinations Against Non-Small Cell Lung Cancer (NSCLC): Translational Insights

Key Points

The study aims to investigate the synergistic effects of pemetrexed and osimertinib combinations and the underlying pharmacokinetic/pharmacodynamic mechanisms.
Assessed potential pharmacokinetic drug-drug interactions at cellular and plasma levels.
Developed a quantitative system pharmacology model linking drug disposition to folate biology and EGFR signaling.
Evaluated the impact of sequential versus concurrent drug administration on cancer cell death and tumor growth.
No significant pharmacokinetic drug-drug interactions were identified, supporting a pharmacodynamic-driven synergy.
The model demonstrated that sequential pemetrexed followed by osimertinib outperforms concurrent administration in inducing cancer cell apoptosis.
Sensitivity analysis revealed that variations in osimertinib sensitivity and the pro-apoptotic protein Bim are crucial for treatment success.

Abstract

Background and Objectives: Combining osimertinib (OSI) with pemetrexed (PEM) can enhance antitumor efficacy; however, the benefit is schedule-dependent. Our previous pharmacodynamic (PD) study showed that concurrent PEM + OSI is limited by OSI-induced G1 arrest, attenuating early PEM cytotoxicity. In contrast, sequential PEM→OSI allows PEM to fully induce S-phase arrest and DNA damage but elicits a pro-survival EGFR rebound; subsequent OSI suppresses this rebound and promotes apoptosis of damaged cells, yielding strong synergy. Here, we investigated whether pharmacokinetic (PK) drug–drug interactions (DDIs) contribute to this synergy and predicted the relative advantage of PEM→OSI versus PEM + OSI under clinically relevant conditions using a PK/PD approach. Method and Results: Potential PK-DDIs were assessed at cellular uptake, plasma exposure, and intratumoral distribution levels. No meaningful PK-DDIs were observed, supporting a primary PD-driven synergy. We integrated mouse PK with in vitro/in vivo PD data to build a mechanistic Quantitative System Pharmacology (QSP)–PK–PD model linking drug disposition to folate biology, Epidermal Growth Factor Receptor (EGFR) signaling, and tumor growth inhibition. The model recapitulated schedule dependence and explained PEM→OSI superiority: PEM initiates damage and EGFR compensatory rebound, after which OSI suppresses EGFR signaling and enhances apoptosis. In contrast, concurrent PEM + OSI induced G1 arrest, reduced the pool of damaged apoptosis-susceptible cells, and weakened the synergy. Global sensitivity analysis identified intrinsic OSI sensitivity and the pro-apoptotic protein Bim as key determinants; reduced OSI sensitivity or Bim activity diminished the advantage of the sequential strategy. The simulations indicated that OSI can start 48 h after PEM exposure (no extended drug holiday is needed) and that the PEM→OSI benefit remains robust across heterogeneity, including BIM-deletion polymorphisms and inter-individual variability in tumor drug sensitivity. Conclusions: This mechanism-based QSP–PK–PD framework connects whole-body PK to core PD processes, explains schedule-dependent synergy, and supports optimization of sequencing intervals and identification of likely responders.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper